ClinicalTrials.gg
CompletedNCT03987295Updated Dec 5, 2025Results posted

A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)

A Phase 2 interventional study of AL001 in Frontotemporal Dementia, sponsored by Alector Inc.. Completed at 12 sites in 6 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-12-05.

Sponsored by Alector Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 103 studies in Frontotemporal Dementia with a site in United States — 31 open to participants now, 45 under way, none of them phase 3. Frontotemporal Dementia · United States.

Enrollment
44th of 66
33 · median 60
Started
2019
with 6 others
Phase 2
14 of 103
4 open now
Registered
52nd of 103
by date
Lead sponsor
4 of 103
Alector Inc.

Among the 103 studies in Frontotemporal Dementia with a site in United States, this one is the 44th largest by enrollment of the 66 interventional ones that give a count, is one of 7 that started in 2019, is one of 14 in phase 2, and was the 52nd registered.

Frontotemporal Dementia

208 studies on the registry are indexed under Frontotemporal Dementia; 72 are open to participants now.

Browse Frontotemporal Dementia studies →

Open to participants now

31 of the 103 studies in Frontotemporal Dementia with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 51 Frontotemporal Dementia studies recruiting now, 29 (57%) set no upper age limit and 5 (10%) stop at 75 or younger; 6 take children under 18; 30 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Frontotemporal Dementia with a site in United States, or all of them as a file.
02

Study summary

A Phase 2 open label study evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AL001 in participants with a Granulin mutation or C9orf72 mutation causative of frontotemporal dementia.

Read the detailed description

This is a Phase 2, multicenter, open label study evaluating the safety, tolerability, PK and PD of AL001 administered intravenously in participants with a Granulin mutation or C9orf72 mutation causative of frontotemporal dementia.

03

Conditions studied

  • Frontotemporal Dementia
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At screening, female participants must be nonpregnant and nonlactating
  • In good physical health on the basis of no findings from medical history, physical examinations (PEs), laboratory tests, ECGs, and vital signs.
  • Participant is a carrier of a loss of function progranulin gene (GRN) mutation or carrier of a hexanucleotide repeat expansion C9orf72 mutation

Exclusion criteria

Exclusion Criteria:

  • Known history of severe allergic, anaphylactic, or other reactions to chimeric, human, or humanized antibodies or fusion proteins.
  • History of alcohol abuse or substance abuse
  • Participant resides in a skilled nursing facility, convalescent home, or long term care facility
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Granulin and C9orf72

    IV administration of AL001; 60 mg/kg, every 4 weeks \[q4w\]

    Drug: AL001

Interventions

  • DrugAL001

    60 mg/kg of AL001 every 4 weeks

06

What researchers measure

Primary outcomes

  1. Severity of TEAEs

    Number of TEAEs categorized by severity

    Time frame: 197 weeks

  2. Severity of Treatment-Related TEAEs

    Number of treatment-related TEAEs categorized by severity

    Time frame: 197 weeks

  3. Any TEAE Leading to Study Drug Discontinuation

    Number of TEAEs leading to study drug discontinuation

    Time frame: 197 weeks

  4. Immunogenicity Antidrug Antibodies (ADA) Titer

    Titer values of antidrug antibodies (ADAs) in participants receiving latozinemab at week 97/Part 1 end of study

    Time frame: 97 weeks

  5. Confirmatory Immunogenicity Antidrug Antibodies (ADA) Responses

    Presence of confirmatory antidrug antibodies (ADAs) in participants who test positive for ADA at week 97 (Part 1 End of Study).

    Time frame: 97 weeks

  6. Change From Baseline in Sheehan Suicidality Tracking Scale

    The Sheehan Suicidality Tracking Scale (S-STS) is a structured assessment tool used to evaluate the presence, severity, and frequency of suicidal ideation and behavior. It includes items that address passive thoughts of death, active suicidal ideation, intent, planning, suicide attempts, and non-suicidal self-injury. The S-STS total score ranges from 0 to 64, based on 16 items each rated from 0 (not at all) to 4 (extremely), with higher scores indicating greater severity of suicidal ideation, intent, or behavior. The total score provides a quantitative measure of suicidality severity and is sensitive to change over time, making it suitable for clinical monitoring and research use.

    Time frame: 197 weeks

Secondary outcomes

  1. Longitudinal Percent Change From Baseline of CSF PGRN

    The percent change from baseline to specified timepoints of PGRN in CSF. The baseline visit is labeled as week 1 and therefore the 96th week is labeled as week 97.

    Time frame: 97 weeks

  2. Longitudinal Percent Change From Baseline in Plasma PGRN

    The percent change from baseline to specified timepoints for PGRN in plasma. The baseline visit is labeled as week 1 and therefore the 96th week is labeled as week 97.

    Time frame: 97 weeks

  3. Longitudinal Levels of Sortilin in WBCs

    The overall change from baseline in Sortilin in WBCs.

    Time frame: 97 weeks

  4. Latozinemab Concentration in Serum

    Serum concentration of Latozinemab at week 97.

    Time frame: 97 weeks

  5. Cmax of Latozinemab at Specified Timepoints

    Maximum observed concentration of Latozinemab at week 96 of treatment.

    Time frame: 97 weeks

  6. Ctrough of Latozinemab at Specified Timepoints

    Trough concentration of Latozinemab at week 96 of treatment

    Time frame: 97 weeks

  7. ARCmax of Latozinemab

    Ratio of latozinemab Cmax at week 61 to the Cmax at week 1

    Time frame: 61 weeks

07

Results

Posted Aug 22, 2025
Limitations and caveats
The study had the following limitations: * No placebo control arm * Small number of participants * A high number of participants discontinued the study due to disease progression

Participant flow

Participant flow — Overall Study
MilestoneaFTD-GRNFTD-GRNFTD-C9orf72
Started51216
Completed556
Not completed0710

Outcome measures

PrimarySeverity of TEAEs

Number of TEAEs categorized by severity

Time frame:
197 weeks
Reported as:
Number · TEAEs (all)
Severity of TEAEs
TEAEs (all)aFTD-GRNFTD-GRNFTD-C9orf72
Mild435884
Moderate4924
Severe314
Life Threatening000
Death001
PrimarySeverity of Treatment-Related TEAEs

Number of treatment-related TEAEs categorized by severity

Time frame:
197 weeks
Reported as:
Number · TEAEs (treatment-related)
Severity of Treatment-Related TEAEs
TEAEs (treatment-related)aFTD-GRNFTD-GRNFTD-C9orf72
Mild5112
Moderate115
Severe000
Life Threatening000
Death000
PrimaryAny TEAE Leading to Study Drug Discontinuation

Number of TEAEs leading to study drug discontinuation

Time frame:
197 weeks
Reported as:
Number · TEAE leading to discontinuation
Any TEAE Leading to Study Drug Discontinuation
TEAE leading to discontinuationaFTD-GRNFTD-GRNFTD-C9orf72
Any TEAE Leading to Study Drug Discontinuation011
PrimaryImmunogenicity Antidrug Antibodies (ADA) Titer

Titer values of antidrug antibodies (ADAs) in participants receiving latozinemab at week 97/Part 1 end of study

Time frame:
97 weeks
Reported as:
Median · Titers
Immunogenicity Antidrug Antibodies (ADA) Titer
TitersaFTD-GRNFTD-GRNFTD-C9orf72
Week 2 - ADA Titer320.0 (20 to 5120)20.0 (20 to 2560)40.0 ± 0.00
Week 13 - ADA Titer160.0 (20 to 2560)160.0 (160 to 640)120.0 (80 to 160)
Week 25 - ADA Titer320.0 (320 to 320)330.0 (20 to 640)80.0 (20 to 160)
Week 37 - ADA Titer0 (0 to 0)80.0 (20 to 320)90.0 (20 to 160)
Week 49 - ADA Titer0 (0 to 0)320.0 (40 to 640)20.0 (20 to 20)
Week 61 - ADA Titer0 (0 to 0)0 (0 to 0)160.0 (160 to 160)
Week 73 - ADA Titer0 (0 to 0)160.0 (160 to 160)0 (0 to 0)
Week 85 - ADA Titer0 (0 to 0)160.0 (160 to 160)20.0 (20 to 20)
Week 97 - ADA Titer20.0 (20 to 20)0 (0 to 0)160.0 (160 to 160)
PrimaryConfirmatory Immunogenicity Antidrug Antibodies (ADA) Responses

Presence of confirmatory antidrug antibodies (ADAs) in participants who test positive for ADA at week 97 (Part 1 End of Study).

Time frame:
97 weeks
Reported as:
Count of participants · Participants
Confirmatory Immunogenicity Antidrug Antibodies (ADA) Responses
ParticipantsaFTD-GRNFTD-GRNFTD-C9orf72
ADA Positive102
ADA Negative457
PrimaryChange From Baseline in Sheehan Suicidality Tracking Scale

The Sheehan Suicidality Tracking Scale (S-STS) is a structured assessment tool used to evaluate the presence, severity, and frequency of suicidal ideation and behavior. It includes items that address passive thoughts of death, active suicidal ideation, intent, planning, suicide attempts, and non-suicidal self-injury. The S-STS total score ranges from 0 to 64, based on 16 items each rated from 0 (not at all) to 4 (extremely), with higher scores indicating greater severity of suicidal ideation, intent, or behavior. The total score provides a quantitative measure of suicidality severity and is sensitive to change over time, making it suitable for clinical monitoring and research use.

Time frame:
197 weeks
Reported as:
Mean · Scores
Change From Baseline in Sheehan Suicidality Tracking Scale
ScoresaFTD-GRNFTD-GRNFTD-C9orf72
Change From Baseline in Sheehan Suicidality Tracking Scale0 ± 000 ± 0
SecondaryLongitudinal Percent Change From Baseline of CSF PGRN

The percent change from baseline to specified timepoints of PGRN in CSF. The baseline visit is labeled as week 1 and therefore the 96th week is labeled as week 97.

Time frame:
97 weeks
Reported as:
Mean · percent change of ug/L
Longitudinal Percent Change From Baseline of CSF PGRN
percent change of ug/LaFTD-GRNFTD-GRNFTD-C9orf72
Week 49198.16 ± 110.255104.05 ± 103.349101.61 ± 38.492
Week 97189.46 ± 113.80259.73 ± 24.034144.73 ± 54.994
SecondaryLongitudinal Percent Change From Baseline in Plasma PGRN

The percent change from baseline to specified timepoints for PGRN in plasma. The baseline visit is labeled as week 1 and therefore the 96th week is labeled as week 97.

Time frame:
97 weeks
Reported as:
Mean · percent change in ug/L
Longitudinal Percent Change From Baseline in Plasma PGRN
percent change in ug/LaFTD-GRNFTD-GRNFTD-C9orf72
Week 49177.39 ± 51.352151.32 ± 59.321178.82 ± 58.406
Week 97185.37 ± 43.763188.12 ± 47.847157.93 ± 92.695
SecondaryLongitudinal Levels of Sortilin in WBCs

The overall change from baseline in Sortilin in WBCs.

Time frame:
97 weeks

No measurements were reported for this outcome.

SecondaryLatozinemab Concentration in Serum

Serum concentration of Latozinemab at week 97.

Time frame:
97 weeks
Reported as:
Mean · ng/mL
Latozinemab Concentration in Serum
ng/mLaFTD-GRNFTD-GRNFTD-C9orf72
Latozinemab Concentration in Serum236000 ± 69100250000 ± 24700265000 ± 77000
SecondaryCmax of Latozinemab at Specified Timepoints

Maximum observed concentration of Latozinemab at week 96 of treatment.

Time frame:
97 weeks
Reported as:
Mean · ug/mL
Cmax of Latozinemab at Specified Timepoints
ug/mLaFTD-GRNFTD-GRNFTD-C9orf72
Cmax of Latozinemab at Specified Timepoints1810 ± 3521320 ± 2551510 ± 145
SecondaryCtrough of Latozinemab at Specified Timepoints

Trough concentration of Latozinemab at week 96 of treatment

Time frame:
97 weeks
Reported as:
Mean · ug/mL
Ctrough of Latozinemab at Specified Timepoints
ug/mLaFTD-GRNFTD-GRNFTD-C9orf72
Ctrough of Latozinemab at Specified Timepoints236 ± 69.1250 ± 24.7252 ± 66.7
SecondaryARCmax of Latozinemab

Ratio of latozinemab Cmax at week 61 to the Cmax at week 1

Time frame:
61 weeks
Reported as:
Mean · Ratio
ARCmax of Latozinemab
RatioaFTD-GRNFTD-GRNFTD-C9orf72
ARCmax of Latozinemab1.22 ± 0.1921.23 ± 0.2361.39 ± 0.712

Adverse events

Collected over 197 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
aFTD-GRN0/5 (0%)1/5 (20%)4/5 (80%)
FTD-GRN0/12 (0%)3/12 (25%)9/12 (75%)
FTD-C9orf721/16 (6.3%)2/16 (12.5%)13/16 (81.3%)
Most frequent serious events
Most frequent serious events
EventaFTD-GRNFTD-GRNFTD-C9orf72
Lip and/or oral cavity cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/50/120/16
Amyotrophic lateral sclerosisNervous system disorders0/50/122/16
Procedural pneumothoraxInjury, poisoning and procedural complications0/51/120/16
Deep vein thrombosisVascular disorders0/51/120/16
SyncopeNervous system disorders0/51/120/16
AggressionPsychiatric disorders0/50/121/16
Most frequent other events
Showing 10 of 141
Most frequent other events
EventaFTD-GRNFTD-GRNFTD-C9orf72
FallInjury, poisoning and procedural complications2/55/127/16
DizzinessNervous system disorders2/50/120/16
Back painMusculoskeletal and connective tissue disorders2/50/120/16
COVID-19Infections and infestations2/50/125/16
Upper respiratory tract infectionInfections and infestations2/50/121/16
Urinary tract infectionInfections and infestations1/52/126/16
Subclavian artery occlusionVascular disorders1/50/120/16
Infusion site extravasationGeneral disorders1/50/120/16
Infusion site painGeneral disorders1/50/120/16
Infusion site paraesthesiaGeneral disorders1/50/120/16

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)aFTD-GRNFTD-GRNFTD-C9orf72Total
<=18 years0000
Between 18 and 65 years571123
>=65 years05510
Age, Continuous
Age, Continuous(years)aFTD-GRNFTD-GRNFTD-C9orf72Total
Median59.0 (32 to 63)59.5 (48 to 78)60.0 (40 to 74)59.0 (32 to 78)
Sex: Female, Male
Sex: Female, Male(Participants)aFTD-GRNFTD-GRNFTD-C9orf72Total
Female14914
Male48719
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)aFTD-GRNFTD-GRNFTD-C9orf72Total
Hispanic or Latino0202
Not Hispanic or Latino5101631
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)aFTD-GRNFTD-GRNFTD-C9orf72Total
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White5101631
More than one race0000
Unknown or Not Reported0202
08

Study locations

12 sites
  • UCSF
    San Francisco, California 94158, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • The Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases UT Health San Antonio
    San Antonio, Texas 78229, United States
  • Lawson Health Research Institute, St. Joseph's
    London, Ontario N6A 4V2, Canada
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario M4N 3M5, Canada
  • Technical University of Munich
    München, 81675, Germany
  • University of Ulm
    Ulm, 89081, Germany
  • University of Brescia
    Brescia, 25123, Italy
  • Brain Research Center - PPDS
    Amsterdam, 1081GN, Netherlands
  • Erasmus University Medical Center
    Rotterdam, 3015 GD, Netherlands
  • University College London
    London, WC1N 3BG, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in Jun 2024, 56 months.

Results were first posted in Aug 2025, 1 year 2 months after primary completion.

Of 19 phase 2 interventional studies under Frontotemporal Dementia, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 64. This study's 56 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2019
First posted
Jun 17, 2019
StartActual
Sep 27, 2019
Primary completionActual
Jun 5, 2024
CompletionActual
Jun 5, 2024
Results first posted
Aug 22, 2025
Last update
Dec 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03987295
Lead sponsor
Alector Inc.
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 17, 2019
Start date
Sep 27, 2019
Primary completion
Jun 5, 2024
Completion
Jun 5, 2024
Results posted
Aug 22, 2025
Last update
Dec 5, 2025

Study contacts

Peter Ljubenkov, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Latozinemab

Start the discussion